Clinical Pharmacokinetics and Pharmacodynamics of Cediranib View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-07

AUTHORS

Weifeng Tang, Alex McCormick, Jianguo Li, Eric Masson

ABSTRACT

Cediranib potently and selectively inhibits all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), and clinical studies have shown that it is effective in patients with ovarian cancer at a dose of 20 mg/day. Cediranib is absorbed moderately slowly; a high-fat meal reduced the cediranib area under the plasma concentration-time curve (AUC) by 24% and maximum plasma concentration (C max) by 33%. Cediranib binds to serum albumin and α1-acid glycoprotein; protein binding in human plasma is approximately 95%. The cediranib AUC and C max increase proportionally with dose from 0.5 to 60 mg, and cediranib has linear pharmacokinetics (PK) over time. Cediranib is metabolized via flavin-containing monooxygenase 1 and 3 (FMO1, FMO3) and uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A4. Cediranib and its metabolites are mainly excreted in faeces (59%), with <1% of unchanged drug being excreted in urine. The apparent oral clearance is moderate and the mean terminal half-life is 22 h. Cediranib is a substrate of multidrug resistance-1 (MDR1) protein (also known as P-glycoprotein [P-gp]). Coadministration with ketoconazole, a potent P-gp inhibitor, increases cediranib AUC at steady-state (AUCss) in patients by 21%, while coadministration with rifampicin, a potent inducer of P-gp, decreases cediranib AUCss by 39%. Administration of cediranib with chemotherapies demonstrated minimal PK impact on each other. No dose adjustment is recommended for patients with mild or moderate hepatic or renal impairment, and no dose adjustment is needed on the basis of age and body weight. A pooled analysis at doses of 0.5-60 mg showed no significant increase in QTc intervals. Increases in blood pressure and the incidence of diarrhoea were associated with increased cediranib dose and systemic exposure. More... »

PAGES

689-702

References to SciGraph publications

  • 2012-02. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-09. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer in BRITISH JOURNAL OF CANCER
  • 2011-09. A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-09. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors in CHILD'S NERVOUS SYSTEM
  • 2009-11. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2002-10. VEGF and the quest for tumour angiogenesis factors in NATURE REVIEWS CANCER
  • 2012-08. Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer in INVESTIGATIONAL NEW DRUGS
  • 2013-02. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2007-10. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC) in INVESTIGATIONAL NEW DRUGS
  • 2011-12. Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study in INVESTIGATIONAL NEW DRUGS
  • 2016-03. Cediranib in ovarian cancer: state of the art and future perspectives in TUMOR BIOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s40262-016-0488-y

    DOI

    http://dx.doi.org/10.1007/s40262-016-0488-y

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1020223111

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/27943222


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Kinase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Quinazolines", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "AstraZeneca (United States)", 
              "id": "https://www.grid.ac/institutes/grid.418152.b", 
              "name": [
                "Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicines, AstraZeneca, One MedImmune Way, 20878, Gaithersburg, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tang", 
            "givenName": "Weifeng", 
            "id": "sg:person.012231652735.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012231652735.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AstraZeneca (United Kingdom)", 
              "id": "https://www.grid.ac/institutes/grid.417815.e", 
              "name": [
                "DMPK Oncology, AstraZeneca, Alderley Park, Cheshire, UK", 
                "DMPK Consulting UK Limited, Congleton, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "McCormick", 
            "givenName": "Alex", 
            "id": "sg:person.013164443305.66", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013164443305.66"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AstraZeneca (United States)", 
              "id": "https://www.grid.ac/institutes/grid.418152.b", 
              "name": [
                "Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicines, AstraZeneca, 35 Gatehouse Drive, 02451, Waltham, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Li", 
            "givenName": "Jianguo", 
            "id": "sg:person.01176332132.74", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176332132.74"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AstraZeneca (United States)", 
              "id": "https://www.grid.ac/institutes/grid.418152.b", 
              "name": [
                "Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicines, AstraZeneca, 35 Gatehouse Drive, 02451, Waltham, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Masson", 
            "givenName": "Eric", 
            "id": "sg:person.014363567577.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014363567577.38"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s10637-010-9484-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001503662", 
              "https://doi.org/10.1007/s10637-010-9484-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10637-010-9484-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001503662", 
              "https://doi.org/10.1007/s10637-010-9484-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2009.22.2273", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007423526"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2007.14.4741", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008379835"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13277-015-4781-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009328495", 
              "https://doi.org/10.1007/s13277-015-4781-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1074/jbc.m010173200", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010348497"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0140-6736(07)61904-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010511397"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.ejca.2013.11.032", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011092448"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-011-1723-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012330932", 
              "https://doi.org/10.1007/s00280-011-1723-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1124/dmd.110.033159", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014178677"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2010.30.9674", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018237901"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-009-0979-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019049611", 
              "https://doi.org/10.1007/s00280-009-0979-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-009-0979-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019049611", 
              "https://doi.org/10.1007/s00280-009-0979-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-009-0979-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019049611", 
              "https://doi.org/10.1007/s00280-009-0979-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/carcin/bgl113", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019148962"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-05-0219", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019904321"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.ejca.2011.12.022", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022488830"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1535-7163.mct-08-0182", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022659267"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.3109/03602538409033561", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024663893"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.ejca.2008.10.022", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024853831"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-06-2636", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025921083"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-010-1534-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026678014", 
              "https://doi.org/10.1007/s00280-010-1534-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-13-1881", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031670774"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/cad.0b013e32835bd1d2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033915027"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/cad.0b013e32835bd1d2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033915027"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00381-015-2812-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034613006", 
              "https://doi.org/10.1007/s00381-015-2812-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/0008-5472.can-04-4409", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035055121"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-06-2743", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035255845"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2011.334", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035908853", 
              "https://doi.org/10.1038/bjc.2011.334"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2011.334", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035908853", 
              "https://doi.org/10.1038/bjc.2011.334"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1128/aac.46.1.160-165.2002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036042824"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1535-7163.mct-07-0142", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038535674"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc909", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040662917", 
              "https://doi.org/10.1038/nrc909"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc909", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040662917", 
              "https://doi.org/10.1038/nrc909"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-012-2038-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041209117", 
              "https://doi.org/10.1007/s00280-012-2038-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2006.07.2066", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042068572"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1124/dmd.114.059097", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043833858"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.ejca.2009.12.023", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043836404"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-08-0761", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044221269"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1535-7163.mct-10-0976", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045258178"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10637-011-9693-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045364743", 
              "https://doi.org/10.1007/s10637-011-9693-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10637-011-9693-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045364743", 
              "https://doi.org/10.1007/s10637-011-9693-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1517/13543780903183528", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047524662"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/0008-5472.can-07-5809", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048663997"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10637-007-9050-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050677478", 
              "https://doi.org/10.1007/s10637-007-9050-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10637-007-9050-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050677478", 
              "https://doi.org/10.1007/s10637-007-9050-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0140-6736(15)01167-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052007600"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0140-6736(15)01167-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052007600"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1074628562", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/bcp.13266", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083847995"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2017-07", 
        "datePublishedReg": "2017-07-01", 
        "description": "Cediranib potently and selectively inhibits all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), and clinical studies have shown that it is effective in patients with ovarian cancer at a dose of 20\u00a0mg/day. Cediranib is absorbed moderately slowly; a high-fat meal reduced the cediranib area under the plasma concentration-time curve (AUC) by 24% and maximum plasma concentration (C max) by 33%. Cediranib binds to serum albumin and \u03b11-acid glycoprotein; protein binding in human plasma is approximately 95%. The cediranib AUC and C max increase proportionally with dose from 0.5 to 60\u00a0mg, and cediranib has linear pharmacokinetics (PK) over\u00a0time. Cediranib is metabolized via flavin-containing monooxygenase 1 and 3 (FMO1, FMO3) and uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A4. Cediranib and its metabolites are mainly excreted in faeces (59%), with <1% of unchanged drug being excreted in urine. The apparent oral clearance is moderate and the mean terminal half-life is 22\u00a0h. Cediranib is a substrate of multidrug resistance-1 (MDR1) protein (also known as P-glycoprotein [P-gp]). Coadministration with ketoconazole, a potent P-gp inhibitor, increases cediranib AUC at steady-state (AUCss) in patients by 21%, while coadministration with rifampicin, a potent inducer of P-gp, decreases cediranib AUCss by 39%. Administration of cediranib with chemotherapies demonstrated minimal PK impact on each other. No dose adjustment is recommended for patients with mild or moderate hepatic or renal impairment, and no dose adjustment is needed on the basis of age and body weight. A pooled analysis at doses of 0.5-60\u00a0mg showed no significant increase in QTc intervals. Increases in blood pressure and the incidence of diarrhoea were associated with increased cediranib dose and systemic exposure.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s40262-016-0488-y", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1085321", 
            "issn": [
              "0312-5963", 
              "1179-1926"
            ], 
            "name": "Clinical Pharmacokinetics", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "56"
          }
        ], 
        "name": "Clinical Pharmacokinetics and Pharmacodynamics of Cediranib", 
        "pagination": "689-702", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "605b3ff3af4352581348309c15e58dacc96f29ebd8934b533b8f4ac628df2fba"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "27943222"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "7606849"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s40262-016-0488-y"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1020223111"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s40262-016-0488-y", 
          "https://app.dimensions.ai/details/publication/pub.1020223111"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T12:25", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87104_00000000.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://link.springer.com/10.1007%2Fs40262-016-0488-y"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40262-016-0488-y'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40262-016-0488-y'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40262-016-0488-y'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40262-016-0488-y'


     

    This table displays all metadata directly associated to this object as RDF triples.

    248 TRIPLES      21 PREDICATES      75 URIs      26 LITERALS      14 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s40262-016-0488-y schema:about N1477e1f78ff24b7c9cb7159c83d716f0
    2 N1621de6028a146a58367e81660decebd
    3 N33114ff498a24e39860a9cdd8035acad
    4 Nd94d8cbd2d964529be0e9ca29afd64ce
    5 Nec54203c2a6a4372939a3c1099f0ba37
    6 anzsrc-for:11
    7 anzsrc-for:1115
    8 schema:author N8e7002abf6084b69b9a9b115c057d8c4
    9 schema:citation sg:pub.10.1007/s00280-009-0979-8
    10 sg:pub.10.1007/s00280-010-1534-3
    11 sg:pub.10.1007/s00280-011-1723-8
    12 sg:pub.10.1007/s00280-012-2038-0
    13 sg:pub.10.1007/s00381-015-2812-5
    14 sg:pub.10.1007/s10637-007-9050-y
    15 sg:pub.10.1007/s10637-010-9484-5
    16 sg:pub.10.1007/s10637-011-9693-6
    17 sg:pub.10.1007/s13277-015-4781-4
    18 sg:pub.10.1038/bjc.2011.334
    19 sg:pub.10.1038/nrc909
    20 https://app.dimensions.ai/details/publication/pub.1074628562
    21 https://doi.org/10.1016/j.ejca.2008.10.022
    22 https://doi.org/10.1016/j.ejca.2009.12.023
    23 https://doi.org/10.1016/j.ejca.2011.12.022
    24 https://doi.org/10.1016/j.ejca.2013.11.032
    25 https://doi.org/10.1016/s0140-6736(07)61904-7
    26 https://doi.org/10.1016/s0140-6736(15)01167-8
    27 https://doi.org/10.1074/jbc.m010173200
    28 https://doi.org/10.1093/carcin/bgl113
    29 https://doi.org/10.1097/cad.0b013e32835bd1d2
    30 https://doi.org/10.1111/bcp.13266
    31 https://doi.org/10.1124/dmd.110.033159
    32 https://doi.org/10.1124/dmd.114.059097
    33 https://doi.org/10.1128/aac.46.1.160-165.2002
    34 https://doi.org/10.1158/0008-5472.can-04-4409
    35 https://doi.org/10.1158/0008-5472.can-07-5809
    36 https://doi.org/10.1158/1078-0432.ccr-05-0219
    37 https://doi.org/10.1158/1078-0432.ccr-06-2636
    38 https://doi.org/10.1158/1078-0432.ccr-06-2743
    39 https://doi.org/10.1158/1078-0432.ccr-08-0761
    40 https://doi.org/10.1158/1078-0432.ccr-13-1881
    41 https://doi.org/10.1158/1535-7163.mct-07-0142
    42 https://doi.org/10.1158/1535-7163.mct-08-0182
    43 https://doi.org/10.1158/1535-7163.mct-10-0976
    44 https://doi.org/10.1200/jco.2006.07.2066
    45 https://doi.org/10.1200/jco.2007.14.4741
    46 https://doi.org/10.1200/jco.2009.22.2273
    47 https://doi.org/10.1200/jco.2010.30.9674
    48 https://doi.org/10.1517/13543780903183528
    49 https://doi.org/10.3109/03602538409033561
    50 schema:datePublished 2017-07
    51 schema:datePublishedReg 2017-07-01
    52 schema:description Cediranib potently and selectively inhibits all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), and clinical studies have shown that it is effective in patients with ovarian cancer at a dose of 20 mg/day. Cediranib is absorbed moderately slowly; a high-fat meal reduced the cediranib area under the plasma concentration-time curve (AUC) by 24% and maximum plasma concentration (C <sub>max</sub>) by 33%. Cediranib binds to serum albumin and α1-acid glycoprotein; protein binding in human plasma is approximately 95%. The cediranib AUC and C <sub>max</sub> increase proportionally with dose from 0.5 to 60 mg, and cediranib has linear pharmacokinetics (PK) over time. Cediranib is metabolized via flavin-containing monooxygenase 1 and 3 (FMO1, FMO3) and uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A4. Cediranib and its metabolites are mainly excreted in faeces (59%), with &lt;1% of unchanged drug being excreted in urine. The apparent oral clearance is moderate and the mean terminal half-life is 22 h. Cediranib is a substrate of multidrug resistance-1 (MDR1) protein (also known as P-glycoprotein [P-gp]). Coadministration with ketoconazole, a potent P-gp inhibitor, increases cediranib AUC at steady-state (AUC<sub>ss</sub>) in patients by 21%, while coadministration with rifampicin, a potent inducer of P-gp, decreases cediranib AUC<sub>ss</sub> by 39%. Administration of cediranib with chemotherapies demonstrated minimal PK impact on each other. No dose adjustment is recommended for patients with mild or moderate hepatic or renal impairment, and no dose adjustment is needed on the basis of age and body weight. A pooled analysis at doses of 0.5-60 mg showed no significant increase in QTc intervals. Increases in blood pressure and the incidence of diarrhoea were associated with increased cediranib dose and systemic exposure.
    53 schema:genre research_article
    54 schema:inLanguage en
    55 schema:isAccessibleForFree false
    56 schema:isPartOf N6730fd51694346fb888d97408dcf606e
    57 Nc3c521d2f3f3456791ec710f8f42e635
    58 sg:journal.1085321
    59 schema:name Clinical Pharmacokinetics and Pharmacodynamics of Cediranib
    60 schema:pagination 689-702
    61 schema:productId N18f0b5eb79374ba5aab2188eb614026c
    62 N22c7061cd9b7437eba8efae81e1db88b
    63 N4049015d10d94450a7b206ca9633367a
    64 N48e9002e4fb247cf9c739a5a25e4ae9a
    65 Nc67b0a23dabe4476b79b34974dc2fce9
    66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020223111
    67 https://doi.org/10.1007/s40262-016-0488-y
    68 schema:sdDatePublished 2019-04-11T12:25
    69 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    70 schema:sdPublisher N8d1d0a2fa7ae434e9ff7f08ef1292b9c
    71 schema:url https://link.springer.com/10.1007%2Fs40262-016-0488-y
    72 sgo:license sg:explorer/license/
    73 sgo:sdDataset articles
    74 rdf:type schema:ScholarlyArticle
    75 N1477e1f78ff24b7c9cb7159c83d716f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    76 schema:name Humans
    77 rdf:type schema:DefinedTerm
    78 N1621de6028a146a58367e81660decebd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    79 schema:name Animals
    80 rdf:type schema:DefinedTerm
    81 N18f0b5eb79374ba5aab2188eb614026c schema:name dimensions_id
    82 schema:value pub.1020223111
    83 rdf:type schema:PropertyValue
    84 N22c7061cd9b7437eba8efae81e1db88b schema:name nlm_unique_id
    85 schema:value 7606849
    86 rdf:type schema:PropertyValue
    87 N33114ff498a24e39860a9cdd8035acad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    88 schema:name Quinazolines
    89 rdf:type schema:DefinedTerm
    90 N4049015d10d94450a7b206ca9633367a schema:name doi
    91 schema:value 10.1007/s40262-016-0488-y
    92 rdf:type schema:PropertyValue
    93 N48e9002e4fb247cf9c739a5a25e4ae9a schema:name readcube_id
    94 schema:value 605b3ff3af4352581348309c15e58dacc96f29ebd8934b533b8f4ac628df2fba
    95 rdf:type schema:PropertyValue
    96 N6730fd51694346fb888d97408dcf606e schema:issueNumber 7
    97 rdf:type schema:PublicationIssue
    98 N8d1d0a2fa7ae434e9ff7f08ef1292b9c schema:name Springer Nature - SN SciGraph project
    99 rdf:type schema:Organization
    100 N8e7002abf6084b69b9a9b115c057d8c4 rdf:first sg:person.012231652735.00
    101 rdf:rest Nd45f4160009448d7bcdd716efa245413
    102 Nb4cb5777c5f34d04a727f485736f7508 rdf:first sg:person.01176332132.74
    103 rdf:rest Ncdce5f6071e64ba080731e7993bff1f0
    104 Nc3c521d2f3f3456791ec710f8f42e635 schema:volumeNumber 56
    105 rdf:type schema:PublicationVolume
    106 Nc67b0a23dabe4476b79b34974dc2fce9 schema:name pubmed_id
    107 schema:value 27943222
    108 rdf:type schema:PropertyValue
    109 Ncdce5f6071e64ba080731e7993bff1f0 rdf:first sg:person.014363567577.38
    110 rdf:rest rdf:nil
    111 Nd45f4160009448d7bcdd716efa245413 rdf:first sg:person.013164443305.66
    112 rdf:rest Nb4cb5777c5f34d04a727f485736f7508
    113 Nd94d8cbd2d964529be0e9ca29afd64ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Antineoplastic Agents
    115 rdf:type schema:DefinedTerm
    116 Nec54203c2a6a4372939a3c1099f0ba37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Protein Kinase Inhibitors
    118 rdf:type schema:DefinedTerm
    119 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    120 schema:name Medical and Health Sciences
    121 rdf:type schema:DefinedTerm
    122 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    123 schema:name Pharmacology and Pharmaceutical Sciences
    124 rdf:type schema:DefinedTerm
    125 sg:journal.1085321 schema:issn 0312-5963
    126 1179-1926
    127 schema:name Clinical Pharmacokinetics
    128 rdf:type schema:Periodical
    129 sg:person.01176332132.74 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
    130 schema:familyName Li
    131 schema:givenName Jianguo
    132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176332132.74
    133 rdf:type schema:Person
    134 sg:person.012231652735.00 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
    135 schema:familyName Tang
    136 schema:givenName Weifeng
    137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012231652735.00
    138 rdf:type schema:Person
    139 sg:person.013164443305.66 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
    140 schema:familyName McCormick
    141 schema:givenName Alex
    142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013164443305.66
    143 rdf:type schema:Person
    144 sg:person.014363567577.38 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
    145 schema:familyName Masson
    146 schema:givenName Eric
    147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014363567577.38
    148 rdf:type schema:Person
    149 sg:pub.10.1007/s00280-009-0979-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019049611
    150 https://doi.org/10.1007/s00280-009-0979-8
    151 rdf:type schema:CreativeWork
    152 sg:pub.10.1007/s00280-010-1534-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026678014
    153 https://doi.org/10.1007/s00280-010-1534-3
    154 rdf:type schema:CreativeWork
    155 sg:pub.10.1007/s00280-011-1723-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012330932
    156 https://doi.org/10.1007/s00280-011-1723-8
    157 rdf:type schema:CreativeWork
    158 sg:pub.10.1007/s00280-012-2038-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041209117
    159 https://doi.org/10.1007/s00280-012-2038-0
    160 rdf:type schema:CreativeWork
    161 sg:pub.10.1007/s00381-015-2812-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034613006
    162 https://doi.org/10.1007/s00381-015-2812-5
    163 rdf:type schema:CreativeWork
    164 sg:pub.10.1007/s10637-007-9050-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1050677478
    165 https://doi.org/10.1007/s10637-007-9050-y
    166 rdf:type schema:CreativeWork
    167 sg:pub.10.1007/s10637-010-9484-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001503662
    168 https://doi.org/10.1007/s10637-010-9484-5
    169 rdf:type schema:CreativeWork
    170 sg:pub.10.1007/s10637-011-9693-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045364743
    171 https://doi.org/10.1007/s10637-011-9693-6
    172 rdf:type schema:CreativeWork
    173 sg:pub.10.1007/s13277-015-4781-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009328495
    174 https://doi.org/10.1007/s13277-015-4781-4
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.1038/bjc.2011.334 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035908853
    177 https://doi.org/10.1038/bjc.2011.334
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1038/nrc909 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040662917
    180 https://doi.org/10.1038/nrc909
    181 rdf:type schema:CreativeWork
    182 https://app.dimensions.ai/details/publication/pub.1074628562 schema:CreativeWork
    183 https://doi.org/10.1016/j.ejca.2008.10.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024853831
    184 rdf:type schema:CreativeWork
    185 https://doi.org/10.1016/j.ejca.2009.12.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043836404
    186 rdf:type schema:CreativeWork
    187 https://doi.org/10.1016/j.ejca.2011.12.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022488830
    188 rdf:type schema:CreativeWork
    189 https://doi.org/10.1016/j.ejca.2013.11.032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011092448
    190 rdf:type schema:CreativeWork
    191 https://doi.org/10.1016/s0140-6736(07)61904-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010511397
    192 rdf:type schema:CreativeWork
    193 https://doi.org/10.1016/s0140-6736(15)01167-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052007600
    194 rdf:type schema:CreativeWork
    195 https://doi.org/10.1074/jbc.m010173200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010348497
    196 rdf:type schema:CreativeWork
    197 https://doi.org/10.1093/carcin/bgl113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019148962
    198 rdf:type schema:CreativeWork
    199 https://doi.org/10.1097/cad.0b013e32835bd1d2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033915027
    200 rdf:type schema:CreativeWork
    201 https://doi.org/10.1111/bcp.13266 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083847995
    202 rdf:type schema:CreativeWork
    203 https://doi.org/10.1124/dmd.110.033159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014178677
    204 rdf:type schema:CreativeWork
    205 https://doi.org/10.1124/dmd.114.059097 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043833858
    206 rdf:type schema:CreativeWork
    207 https://doi.org/10.1128/aac.46.1.160-165.2002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036042824
    208 rdf:type schema:CreativeWork
    209 https://doi.org/10.1158/0008-5472.can-04-4409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035055121
    210 rdf:type schema:CreativeWork
    211 https://doi.org/10.1158/0008-5472.can-07-5809 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048663997
    212 rdf:type schema:CreativeWork
    213 https://doi.org/10.1158/1078-0432.ccr-05-0219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019904321
    214 rdf:type schema:CreativeWork
    215 https://doi.org/10.1158/1078-0432.ccr-06-2636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025921083
    216 rdf:type schema:CreativeWork
    217 https://doi.org/10.1158/1078-0432.ccr-06-2743 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035255845
    218 rdf:type schema:CreativeWork
    219 https://doi.org/10.1158/1078-0432.ccr-08-0761 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044221269
    220 rdf:type schema:CreativeWork
    221 https://doi.org/10.1158/1078-0432.ccr-13-1881 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031670774
    222 rdf:type schema:CreativeWork
    223 https://doi.org/10.1158/1535-7163.mct-07-0142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038535674
    224 rdf:type schema:CreativeWork
    225 https://doi.org/10.1158/1535-7163.mct-08-0182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022659267
    226 rdf:type schema:CreativeWork
    227 https://doi.org/10.1158/1535-7163.mct-10-0976 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045258178
    228 rdf:type schema:CreativeWork
    229 https://doi.org/10.1200/jco.2006.07.2066 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042068572
    230 rdf:type schema:CreativeWork
    231 https://doi.org/10.1200/jco.2007.14.4741 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008379835
    232 rdf:type schema:CreativeWork
    233 https://doi.org/10.1200/jco.2009.22.2273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007423526
    234 rdf:type schema:CreativeWork
    235 https://doi.org/10.1200/jco.2010.30.9674 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018237901
    236 rdf:type schema:CreativeWork
    237 https://doi.org/10.1517/13543780903183528 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047524662
    238 rdf:type schema:CreativeWork
    239 https://doi.org/10.3109/03602538409033561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024663893
    240 rdf:type schema:CreativeWork
    241 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
    242 schema:name DMPK Consulting UK Limited, Congleton, UK
    243 DMPK Oncology, AstraZeneca, Alderley Park, Cheshire, UK
    244 rdf:type schema:Organization
    245 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
    246 schema:name Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicines, AstraZeneca, 35 Gatehouse Drive, 02451, Waltham, MA, USA
    247 Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicines, AstraZeneca, One MedImmune Way, 20878, Gaithersburg, MD, USA
    248 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...